Industry: Biotechnology

Sector: Healthcare

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University for the use of synthetic bryostatin and for the use of bryostatin-like compounds; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix, Inc. is a subsidiary of Petros Pharmaceuticals, Inc.

Synaptogenix Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.